Regenxbio News

It Looks Like REGENXBIO Inc.'s (NASDAQ:RGNX) CEO May Expect Their Salary To Be Put Under The Microscope

Yahoo FinanceMay 25 09:01 ET

PTC Therapeutics Rallies 18% on EU Authorization Update for Translarna

Seeking AlphaMay 20 09:58 ET

Regenxbio(RGNX.US) Officer Sells US$237.22K in Common Stock

$Regenxbio(RGNX.US)$ Officer Mills Kenneth T. sold 15,000 shares of common stock on May 14, 2024 at an average price of $15.8148 for a total value of $237.22K.Source: Announcement What is statement of

moomoo NewsMay 16 17:50 ET

Evaluating Regenxbio: Insights From 9 Financial Analysts

During the last three months, 9 analysts shared their evaluations of Regenxbio (NASDAQ:RGNX), revealing diverse outlooks from bullish to bearish.In the table below, you'll find a summary of their rece

BenzingaMay 15 15:02 ET

REGENXBIO Is Maintained at Buy by HC Wainwright & Co.

REGENXBIO Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMay 15 11:41 ET

Express News | HC Wainwright & Co. Maintains Buy on Regenxbio, Raises Price Target to $38

BenzingaMay 15 11:31 ET

Regenxbio Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 140.51% HC Wainwright & Co. $36 → $38 Maintains Buy 04/12/2024 153.16% Stifel → $40 Maintains B

BenzingaMay 15 11:29 ET

Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), PepGen Inc. (PEPG) and RegenXBio (RGNX)

TipRanksMay 15 06:31 ET

Cantor Picks 14 Undervalued Biotech Stocks Worth a Second Look

Seeking AlphaMay 12 11:00 ET

REGENXBIO Inc. (NASDAQ:RGNX) Shares Could Be 43% Below Their Intrinsic Value Estimate

Key Insights REGENXBIO's estimated fair value is US$27.02 based on 2 Stage Free Cash Flow to Equity REGENXBIO's US$15.44 share price signals that it might be 43% undervalued Analyst price target

Simply Wall StMay 12 08:50 ET

Regenxbio Inc (RGNX) Q1 2024 Earnings: Misses Analyst Revenue and EPS Forecasts

Yahoo FinanceMay 10 14:30 ET

REGENXBIO to Participate in Upcoming Investor Conferences

ROCKVILLE, Md., May 10, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: BofA Securities Health Care Conference 2

PR NewswireMay 10 07:05 ET

Buy Rating Affirmed for RegenXBio Amid Promising Drug Developments and Solid Financials

TipRanksMay 10 01:29 ET

HHS Panel to Vote in Nov. on DMD Screening for Newborns

Seeking AlphaMay 9 18:44 ET

UBS Adjusts Price Target on REGENXBIO to $39 From $43, Maintains Buy Rating

REGENXBIO (RGNX) has an average outperform rating and price target range of $21 to $55, according to analysts polled by Capital IQ. Price: 16.37, Change: -0.30, Percent Change: -1.80

MT NewswiresMay 9 11:11 ET

Earnings Call Summary | Regenxbio(RGNX.US) Q1 2024 Earnings Conference

The following is a summary of the REGENXBIO Inc. (RGNX) Q1 2024 Earnings Call Transcript:Financial Performance:The company's cash reserves increased from $314 million in Dec 2023 to $381 million in Ma

moomoo AIMay 9 10:42 ET · Conference Call

Express News | Regenxbio Inc : Raymond James Cuts Target Price to $42 From $45

ReutersMay 9 07:57 ET

Q1 2024 Regenxbio Inc Earnings Call

Yahoo FinanceMay 9 07:11 ET

RBC Capital Sticks to Its Buy Rating for RegenXBio (RGNX)

TipRanksMay 9 06:54 ET

Regenxbio Inc (RGNX) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress and Robust ...

Yahoo FinanceMay 9 03:46 ET